Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 6 | 2021 | 147 | 1.980 |
Why?
|
| Liver Neoplasms | 6 | 2021 | 195 | 1.350 |
Why?
|
| Li-Fraumeni Syndrome | 3 | 2016 | 3 | 1.340 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2019 | 200 | 0.930 |
Why?
|
| Hepatitis C, Chronic | 2 | 2020 | 39 | 0.870 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 14 | 0.790 |
Why?
|
| Gastric Bypass | 1 | 2021 | 14 | 0.790 |
Why?
|
| Weight Loss | 1 | 2021 | 124 | 0.730 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 18 | 0.730 |
Why?
|
| Gene Silencing | 2 | 2019 | 143 | 0.720 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2020 | 781 | 0.700 |
Why?
|
| DNA Methylation | 2 | 2019 | 301 | 0.700 |
Why?
|
| Antiviral Agents | 1 | 2020 | 148 | 0.670 |
Why?
|
| Medication Adherence | 1 | 2020 | 165 | 0.640 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 284 | 0.640 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2016 | 89 | 0.600 |
Why?
|
| Hepacivirus | 3 | 2018 | 59 | 0.590 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 74 | 0.550 |
Why?
|
| Humans | 35 | 2023 | 34853 | 0.540 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 198 | 0.500 |
Why?
|
| Obesity | 2 | 2021 | 965 | 0.470 |
Why?
|
| Hypertension | 1 | 2021 | 770 | 0.470 |
Why?
|
| Disease Progression | 5 | 2023 | 580 | 0.460 |
Why?
|
| Caveolin 1 | 1 | 2012 | 27 | 0.450 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 39 | 0.430 |
Why?
|
| Gastrointestinal Diseases | 2 | 2023 | 41 | 0.420 |
Why?
|
| Minority Groups | 1 | 2016 | 537 | 0.400 |
Why?
|
| Retrospective Studies | 6 | 2023 | 1961 | 0.390 |
Why?
|
| Female | 18 | 2023 | 19873 | 0.350 |
Why?
|
| Breast Neoplasms | 3 | 2016 | 1426 | 0.350 |
Why?
|
| Male | 16 | 2023 | 18870 | 0.350 |
Why?
|
| Colonic Polyps | 2 | 2020 | 67 | 0.350 |
Why?
|
| Cohort Studies | 3 | 2023 | 1422 | 0.330 |
Why?
|
| Janus Kinase 2 | 1 | 2008 | 31 | 0.320 |
Why?
|
| STAT5 Transcription Factor | 1 | 2008 | 44 | 0.320 |
Why?
|
| Mesoderm | 1 | 2008 | 70 | 0.320 |
Why?
|
| Liver Cirrhosis | 2 | 2018 | 51 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2006 | 5 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 15 | 0.290 |
Why?
|
| Genes, p53 | 1 | 2006 | 24 | 0.290 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 406 | 0.280 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 184 | 0.280 |
Why?
|
| Down-Regulation | 2 | 2012 | 420 | 0.270 |
Why?
|
| Adult | 10 | 2023 | 11034 | 0.270 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 413 | 0.260 |
Why?
|
| Epithelial Cells | 1 | 2008 | 366 | 0.250 |
Why?
|
| Corneal Dystrophies, Hereditary | 2 | 2006 | 2 | 0.250 |
Why?
|
| Middle Aged | 11 | 2023 | 9642 | 0.240 |
Why?
|
| Fibroblasts | 3 | 2016 | 252 | 0.240 |
Why?
|
| Liver Diseases | 1 | 2023 | 31 | 0.240 |
Why?
|
| Azetidines | 1 | 2013 | 7 | 0.240 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 12 | 0.240 |
Why?
|
| Microscopy, Confocal | 2 | 2006 | 210 | 0.230 |
Why?
|
| Pyrroles | 1 | 2013 | 54 | 0.230 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 2128 | 0.230 |
Why?
|
| Blood Coagulation | 1 | 2023 | 22 | 0.230 |
Why?
|
| Autoimmunity | 1 | 2023 | 52 | 0.220 |
Why?
|
| Karyotyping | 2 | 2016 | 46 | 0.220 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 140 | 0.220 |
Why?
|
| Risk Factors | 5 | 2021 | 3414 | 0.210 |
Why?
|
| Hepatitis C | 2 | 2018 | 120 | 0.210 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 173 | 0.210 |
Why?
|
| Aged | 7 | 2022 | 6448 | 0.200 |
Why?
|
| Head and Neck Neoplasms | 1 | 2001 | 73 | 0.200 |
Why?
|
| Signal Transduction | 2 | 2016 | 1802 | 0.190 |
Why?
|
| Chromatography, Thin Layer | 1 | 2010 | 37 | 0.190 |
Why?
|
| Liver Function Tests | 1 | 2020 | 18 | 0.190 |
Why?
|
| beta Catenin | 1 | 2020 | 46 | 0.190 |
Why?
|
| Interferons | 1 | 2020 | 34 | 0.190 |
Why?
|
| Liver | 2 | 2019 | 447 | 0.190 |
Why?
|
| Uterine Diseases | 1 | 2019 | 5 | 0.180 |
Why?
|
| Polyps | 1 | 2019 | 9 | 0.180 |
Why?
|
| Caco-2 Cells | 1 | 2019 | 48 | 0.180 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 52 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2001 | 176 | 0.180 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 49 | 0.180 |
Why?
|
| Crohn Disease | 1 | 2020 | 55 | 0.180 |
Why?
|
| Colitis | 1 | 2020 | 64 | 0.180 |
Why?
|
| Age Factors | 2 | 2020 | 1007 | 0.180 |
Why?
|
| Carrier Proteins | 1 | 2001 | 287 | 0.180 |
Why?
|
| Sex Factors | 2 | 2020 | 859 | 0.180 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 115 | 0.180 |
Why?
|
| Metabolome | 1 | 2019 | 47 | 0.170 |
Why?
|
| Alleles | 1 | 2020 | 284 | 0.170 |
Why?
|
| Indoles | 1 | 2010 | 154 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 85 | 0.170 |
Why?
|
| Biomedical Research | 1 | 2023 | 371 | 0.170 |
Why?
|
| Metabolomics | 1 | 2019 | 76 | 0.170 |
Why?
|
| Viral Load | 1 | 2020 | 300 | 0.170 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 2003 | 72 | 0.160 |
Why?
|
| Incidence | 1 | 2021 | 882 | 0.160 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 608 | 0.160 |
Why?
|
| Genotype | 1 | 2020 | 641 | 0.160 |
Why?
|
| Mutation | 2 | 2006 | 1023 | 0.160 |
Why?
|
| Galactose | 1 | 1996 | 7 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 600 | 0.150 |
Why?
|
| Treatment Outcome | 1 | 2021 | 1349 | 0.150 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2006 | 3 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2017 | 56 | 0.150 |
Why?
|
| Omeprazole | 1 | 2006 | 6 | 0.150 |
Why?
|
| Proton Pump Inhibitors | 1 | 2006 | 9 | 0.140 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 51 | 0.140 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 72 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 638 | 0.140 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1149 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2020 | 775 | 0.140 |
Why?
|
| DNA, Mitochondrial | 1 | 1996 | 165 | 0.140 |
Why?
|
| RNA, Messenger | 1 | 2020 | 1152 | 0.130 |
Why?
|
| Pyridines | 1 | 2016 | 113 | 0.130 |
Why?
|
| Prospective Studies | 3 | 2023 | 1353 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 180 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2020 | 386 | 0.130 |
Why?
|
| Cell Nucleus | 1 | 1996 | 351 | 0.130 |
Why?
|
| Models, Biological | 1 | 2018 | 642 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2020 | 583 | 0.130 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 391 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 484 | 0.120 |
Why?
|
| Phenotype | 1 | 2016 | 650 | 0.120 |
Why?
|
| Cell Line | 4 | 2016 | 1289 | 0.120 |
Why?
|
| DNA | 1 | 1996 | 549 | 0.120 |
Why?
|
| Mitochondria | 1 | 1996 | 454 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 54 | 0.110 |
Why?
|
| Feedback, Physiological | 1 | 2012 | 28 | 0.110 |
Why?
|
| Gene Expression | 3 | 2012 | 639 | 0.110 |
Why?
|
| Benzothiazoles | 1 | 2012 | 20 | 0.110 |
Why?
|
| Benzofurans | 1 | 2012 | 19 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2012 | 36 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 56 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 298 | 0.100 |
Why?
|
| Prevalence | 3 | 2020 | 1425 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2012 | 309 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2012 | 490 | 0.090 |
Why?
|
| United States | 2 | 2017 | 3894 | 0.090 |
Why?
|
| Drug Stability | 2 | 2010 | 110 | 0.080 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 87 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2020 | 727 | 0.070 |
Why?
|
| Ophthalmoscopes | 1 | 2006 | 2 | 0.070 |
Why?
|
| Chromosome Banding | 1 | 2006 | 6 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 49 | 0.070 |
Why?
|
| Homozygote | 1 | 2006 | 75 | 0.070 |
Why?
|
| Heterozygote | 1 | 2006 | 91 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 2333 | 0.070 |
Why?
|
| Logistic Models | 2 | 2020 | 894 | 0.070 |
Why?
|
| Neuroblastoma | 1 | 2006 | 128 | 0.070 |
Why?
|
| DNA Fragmentation | 2 | 2002 | 91 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2008 | 562 | 0.060 |
Why?
|
| Vomiting | 1 | 2023 | 13 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 901 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 480 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2002 | 184 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 30 | 0.060 |
Why?
|
| Fatigue | 1 | 2023 | 79 | 0.060 |
Why?
|
| Etoposide | 1 | 2002 | 21 | 0.060 |
Why?
|
| Troponin | 1 | 2022 | 15 | 0.060 |
Why?
|
| Endodeoxyribonucleases | 1 | 2002 | 29 | 0.050 |
Why?
|
| Osteosarcoma | 1 | 2002 | 24 | 0.050 |
Why?
|
| Proteins | 2 | 2002 | 352 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2002 | 42 | 0.050 |
Why?
|
| Ferritins | 1 | 2022 | 54 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2001 | 59 | 0.050 |
Why?
|
| Diarrhea | 1 | 2022 | 84 | 0.050 |
Why?
|
| Apoptosis | 2 | 2016 | 1317 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2001 | 114 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2001 | 139 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2001 | 89 | 0.050 |
Why?
|
| Laminin | 1 | 2001 | 59 | 0.050 |
Why?
|
| Proteoglycans | 1 | 2001 | 46 | 0.050 |
Why?
|
| DNA Primers | 1 | 2001 | 269 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 107 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 964 | 0.050 |
Why?
|
| Latin America | 1 | 2020 | 41 | 0.050 |
Why?
|
| Cell Division | 1 | 2001 | 296 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2001 | 122 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2001 | 323 | 0.050 |
Why?
|
| Densitometry | 1 | 2010 | 13 | 0.050 |
Why?
|
| Collagen | 1 | 2001 | 162 | 0.050 |
Why?
|
| Limit of Detection | 1 | 2010 | 56 | 0.050 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2010 | 94 | 0.050 |
Why?
|
| Lung | 1 | 2003 | 413 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 605 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 325 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2020 | 98 | 0.050 |
Why?
|
| RNA | 1 | 2001 | 234 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2019 | 75 | 0.040 |
Why?
|
| Corneal Stroma | 1 | 1999 | 6 | 0.040 |
Why?
|
| Endothelium, Corneal | 1 | 1999 | 5 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 370 | 0.040 |
Why?
|
| Stromal Cells | 1 | 1999 | 45 | 0.040 |
Why?
|
| Asthma | 1 | 2003 | 363 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 517 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 109 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 606 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 707 | 0.040 |
Why?
|
| Mice | 3 | 2003 | 5668 | 0.040 |
Why?
|
| Animals | 4 | 2003 | 14307 | 0.040 |
Why?
|
| Anti-Ulcer Agents | 1 | 2006 | 5 | 0.040 |
Why?
|
| Acids | 1 | 2006 | 15 | 0.040 |
Why?
|
| Cricetinae | 1 | 1996 | 217 | 0.040 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 65 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 570 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 404 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 465 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 984 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 903 | 0.030 |
Why?
|
| Adolescent | 1 | 2023 | 5035 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 545 | 0.030 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2012 | 35 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 2012 | 57 | 0.030 |
Why?
|
| Caspases | 2 | 2002 | 132 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2012 | 107 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2012 | 80 | 0.030 |
Why?
|
| Caspase 3 | 2 | 2002 | 194 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2002 | 146 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2002 | 423 | 0.020 |
Why?
|
| Transfection | 2 | 2002 | 496 | 0.020 |
Why?
|
| Drug Design | 1 | 2012 | 154 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 281 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 376 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2012 | 296 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 756 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4012 | 0.020 |
Why?
|
| Ophthalmoscopy | 1 | 2006 | 13 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2006 | 42 | 0.020 |
Why?
|
| Equipment Design | 1 | 2006 | 127 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 555 | 0.020 |
Why?
|
| HIV Infections | 1 | 2017 | 2207 | 0.010 |
Why?
|
| Ovalbumin | 1 | 2003 | 43 | 0.010 |
Why?
|
| Oxidants | 1 | 2003 | 43 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 59 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2003 | 59 | 0.010 |
Why?
|
| Staurosporine | 1 | 2002 | 35 | 0.010 |
Why?
|
| Allergens | 1 | 2003 | 58 | 0.010 |
Why?
|
| Nucleosomes | 1 | 2002 | 27 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 103 | 0.010 |
Why?
|
| Benzamides | 1 | 2003 | 76 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 164 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 13 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2003 | 181 | 0.010 |
Why?
|
| Deoxyribonucleases | 1 | 2002 | 25 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2002 | 78 | 0.010 |
Why?
|
| NAD | 1 | 2002 | 39 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2002 | 85 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 396 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2002 | 180 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 485 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2003 | 306 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2003 | 897 | 0.010 |
Why?
|
| Calcium | 1 | 2002 | 445 | 0.010 |
Why?
|
| Inflammation | 1 | 2003 | 577 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 1530 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 1442 | 0.010 |
Why?
|